TARS
Tarsus Pharmaceuticals, Inc.
Biotechnology · Healthcare · United States
74.20
close · 2026-10-29
value
34
cheaper than peers34
quality
79
stronger fundamentals79
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 4.90× | 75 |
| forward P/E | 31.44× | 26 |
| price to book | 9.26× | 22 |
3 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | -13.7% | 76 |
| operating margin | -11.4% | 73 |
| revenue growth | 69.4% | 72 |
| debt to equity | 25.6% | 42 |
4 of 4 measures available
Facts
| market cap | $3B |
| free cash flow | $67.5M |
| employees | 370 |
| first trade | 2020-10-16 |
| next earnings | 2026-11-03 |
| fundamentals updated | 2026-08-10 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -1.59 | -3.07 | -4.62 | -2.52 |
| free cash flow | -$22.3M | -$89.6M | -$123.0M | -$49.5M |
| net income | -$66.4M | -$115.6M | -$135.9M | -$62.1M |
| revenue | $451.4M | $183.0M | $17.4M | $25.8M |
| unusual items | $0 | -$1.9M | $0 | -$769,000 |